Jae-Young Ha
Senior Vice President AriBio
Seminars
Wednesday 9th December 2026
AR1001 Polypharmacology: Improving Cerebral Perfusion, Inducing Neuroprotection, Enhancing Synaptic Plasticity & Preventing Tau Phosphorylation via PDE5 Inhibition
11:00 am
- Demonstrating how AR1001 induces multiple neuroprotective effects, with potential to be disease-modifying
- Investigating the commercial and clinical variability of AR1001 under POLARIS-AD (global Phase III trial)
- Showing how AR1001 achieves simultaneous multimodal effects while maintaining an exceptional safety profile
Thursday 10th December 2026
Redefining Korean Biopharma Partnerships with China: Addressing the Complex Regulatory & Geopolitical Friction
9:00 am
- Outlining the first example of a Korean CNS asset out-licensed at Phase III vs.typical earlier-stage licensing deals
- Demonstrating how Korean biopharma can retain and elevate their clinical assets to maximize financial returns
- Innovative collaboration models in the biopharma industry between Korea and China
